Comparative study of the use of antihypertensives and their relationship with sars-cov-2
Health Leadership and Quality of Life · 23.02.2025 · 1 · 96
DOI: 10.56294/hl202296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Leadership and Quality of Life, online erschienen am 23.02.2025. Verfasst von Franklin Francisco Castro Mindiola und 1 weiteren Autor:innen. Die Arbeit nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This comparative study analyzed the published scientific evidence about the association between the reduction of severity or mortality due to COVID-19, and the efficiency of the use of Angiotensin Converting Enzyme Inhibitors (ACEIs) and angiotensin receptor blockers (BRAs) compared to other drugs antihypertensives non-ACEI/ARB in hypertensive patients. The objective was to estimate the occurrence of the risk of morbidity, severity or mortality due severe acute respiratory failure in hypertensive patients and the efficacy of angiotensin-converting enzyme (ACE) and inhibitor drugs non-peptic Angio II receptor antagonists (ARBs II) in SARS-Cov-2.The methodology used was the exhaustive bibliographic review of literary bases through the advanced search function of observational studies, clinical trials and meta-analyses that focus on the use of ACE Inhibitors/BRAs in SARS-Cov-2.The ACEI and ARB results demonstrated better efficacy in terms of control of inflammatory processes and low risk of severity due to COVID-19 than CCBs. In addition, several studies affirm that there is a low risk of hospitalization, intubation and mortality from all cardiovascular causes during COVID-19 disease. Therefore, published scientific evidence suggests acceptable safety of the management of ACEIs/ ARBs in SARS-Cov-2 and arterial hypertension in contrast to the few studies where ACEIs / ARBs increased the susceptibility of SARS-Cov-2, resulting in potential systemic damage. Conclusion: The medium-low quality of scientific evidence suggests an urgent need for a new systematic review that includes a greater number of randomized clinical trials, to corroborate the magnitude of the risk of morbidity, severity, and mortality from SARS-Cov-2.
Zitieren
APA
Mindiola, F. F. C., & Cañarte, P. A. S. (2025). Comparative study of the use of antihypertensives and their relationship with sars-cov-2. Health Leadership and Quality of Life, 1, 96. https://doi.org/10.56294/hl202296
Vancouver
Mindiola FFC, Cañarte PAS. Comparative study of the use of antihypertensives and their relationship with sars-cov-2. Health Leadership and Quality of Life. 2025;1:96. doi:10.56294/hl202296
BibTeX
@article{Mindiola2025,
author = {Mindiola, Franklin Francisco Castro and Cañarte, Pilar Asunción Soledispa},
title = {Comparative study of the use of antihypertensives and their relationship with sars-cov-2},
journal = {Health Leadership and Quality of Life},
year = {2025},
volume = {1},
pages = {96},
doi = {10.56294/hl202296}
}
EUVIMED